Pfizer Inc. announced the introduction of Retacrit (epoetin alfa-epbx) injection, the first available biosimilar to Procrit (epoetin alfa) and Epogen (epoetin alfa) in the U.S, at a substantial discount.
Pfizer began shipment of Retacrit to wholesalers in the U.S. on Nov. 12.
Retacrit will be introduced at a Wholesale Acquisition Cost of $11.03 per 1,000 units/mL, which is 57.1 percent below the WAC of Procrit (epoetin alfa) [$25.72 per 1,000 units/mL] and 33.5 percent below the WAC of Epogen (epoetin alfa) [$16.58 per 1,000 units/mL], its reference product.
WAC is not inclusive of discounts to payers, providers, distributors and other purchasing organizations.
The Centers for Medicare and Medicaid Services has granted two unique assigned Q codes for Retacrit: Q5105 for End-Stage Renal Disease on dialysis and Q5106 for non-ESRD.
Additionally, Retacrit qualifies for pass-through status under the hospital outpatient prospective payment system.
Retacrit is Pfizer’s third available biosimilar in the U.S. Pfizer also has an extensive biosimilars pipeline, including three biosimilars products currently accepted for review by the FDA. Pfizer has entered into an agreement with Vifor Pharma Inc. for the commercialization of Retacrit in certain channels.
Pfizer introduces biosimilar Retacrit injection in the U.S. at a substantial discount
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Table of Contents
YOU MAY BE INTERESTED IN
Those anxiously anticipating the release of the U.S. News & World Report‘s evaluation of cancer hospitals will find one intriguing change.


Multiple components of the healthcare and public health systems are currently under scrutiny. One of them is reportedly the U.S. Preventive Services Task Force (USPSTF: “Task Force”), established in 1984 and managed by the Agency for Healthcare Research and Quality. It was created to maintain an ongoing evaluation of disease prevention and screening interventions that...


A study led by researchers at the University of Pennsylvania has found that binary (yes/no) voting at the FDA Oncologic Drugs Advisory Committee can accurately capture the committee members’ perspectives in most cases.


Alan KormanAviv RegevJeffrey C. RathmellThe Cancer Research Institute announced the 2025 recipients of the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology and the Frederick W. Alt Award for New Discoveries in Immunology.

